Nov 10, 2025 • Zacks Commentary
NEUTRAL
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
Nov 08, 2025 • South China Morning Post
SOMEWHAT-BULLISH
6 of the best: the billion-dollar biotechs putting China on the map
The ferocity of China's biopharmaceutical investment boom this year - fuelled by record-breaking licensing of commercial rights to global giants after a three-year slump - may have surprised casual observers. But according to Helen Chen, one of the most respected analysts and advisers in China's ...
Nov 06, 2025 • Motley Fool
SOMEWHAT-BULLISH
Revolution Medicines ( RVMD ) Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETChief Executive Officer - Mark A. GoldsmithContinue reading ...
Oct 28, 2025 • Zacks Commentary
NEUTRAL
Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.
Oct 27, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
Oct 27, 2025 • Motley Fool
NEUTRAL
1 Monster Stock in the Making to Buy and Hold
The company's prospects improve with every clinical win.